TMEM200A (Transmembrane Protein 200A)

Furthermore, we also used Kaplan-Meier curves, multivariate analysis and penalized Cox regression model to identify six genes (C2CD5, CD163, JADE3, BIRC3, TMEM200A, and LINC00877) related to the prognosis of DLBCL. In conclusion, we developed a machine learning model integrating clinical characteristics and gene expression profiles, providing a reliable decision-support tool for DLBCL prognosis and treatment selection.

TMEM200A may also affect EMT through PI3K/AKT signaling, thus influencing the tumor microenvironment. Therefore, in pan-cancers, especially GC, TMEM200A may be a potential biomarker and oncogene.

Conversely, eosinophils is increased in high expression group compared with low expression group. TMEM200A is a potential prognostic biomarker and correlated with immune infiltrates in GC.

A newly established research model and two distinct transcriptome analysis approaches identified novel candidate genes enrolled in CBP resistance development and/or CBP-induced EMT and implied that one-gene targeting could be a better approach than signalling pathway inhibition for influencing both phenomena.